Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 6/20 | 0.39 |
| ▸ | REN | P00797 | 3/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.35 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.35 |
| ▸ | DRD2 | P14416 | 2/20 | 0.33 |
| ▸ | DRD4 | P21917 | 2/20 | 0.33 |
| ▸ | DRD3 | P35462 | 2/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3205328 | 0.90 | REN (0.40) | CHRM1RENCYP3A4 | |
| SCHEMBL3074134 | 0.90 | CHRM1 (0.41) | CHRM1RENCYP3A4 | |
| SCHEMBL3072851 | 0.90 | CHRM1 (0.35) | CHRM1RENCYP3A4CHRM4CHRM5 | |
| SCHEMBL3083202 | 0.90 | REN (0.39) | CHRM1RENCYP3A4 | |
| SCHEMBL3071453 | 0.89 | CHRM1 (0.38) | CHRM1RENCYP3A4 | |
| SCHEMBL3079632 | 0.89 | REN (0.40) | CHRM1RENCYP3A4 | |
| SCHEMBL3064999 | 0.87 | REN (0.46) | CHRM1RENCYP3A4DRD2DRD4 | |
| SCHEMBL3084943 | 0.87 | REN (0.44) | CHRM1RENCYP3A4DRD2DRD4 | |
| SCHEMBL3073886 | 0.87 | REN (0.43) | CHRM1RENCYP3A4 | |
| SCHEMBL3083602 | 0.87 | REN (0.40) | CHRM1RENCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7842688-B2 | Organic compounds | NOVARTIS PHARMA AG (CH) | 2010-11-30 | — | — | US | disclosed |
| US-7790715-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-09-07 | — | — | US | disclosed |
| US-20090012055-A1 | Organic compounds | HEROLD PETER | 2009-01-08 | — | — | US | disclosed |
| US-20070010511-A1 | Organic compounds | NOVARTIS PHARMA AG (CH) | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012055-A1 | Organic compounds | REN, ACE, ACE2 | CHRM1 1675/4885REN 1/4885CYP3A4 29/4885 |
| US-20070010511-A1 | Organic compounds | REN, ACE, ACE2 | CHRM1 1675/4885REN 1/4885CYP3A4 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.